NCT02822157 - Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2023

Conditions

Ovarian Epithelial Cancer

Interventions

DRUG

Olaparib

DRUG

carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly

physician's choice chemotherapy

Trial Locations (1)

Unknown

UZLeuven, Leuven